Drug Type Small molecule drug |
Synonyms 14C JNJ-56136379, JNJ 56136379, JNJ-379 + [2] |
Target |
Action inhibitors |
Mechanism HBV capsid inhibitors(HBV capsid inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H14F4N4O3S |
InChIKeySBVBIDUKSBJYEF-VIFPVBQESA-N |
CAS Registry1638266-40-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 2 | United States | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | United States | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | China | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Japan | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Japan | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Belgium | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Belgium | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Canada | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | Canada | 13 Feb 2018 | |
Hepatitis B, Chronic | Phase 2 | France | 13 Feb 2018 |
Phase 2 | 130 | (Arm 1: JNJ-73763989 (200 Milligrams [mg])+JNJ-56136379 (250 mg)+NA) | jseiyyggqo = wcbdmxpemx ligplvslsw (eapvyvmmbl, yhfgmyorpg - qjwakxwxtk) View more | - | 31 Jul 2024 | ||
Nucleos(t)Ide Analog (Arm 2: Nucleos(t)Ide Analog (NA)) | jseiyyggqo = jctjaxyydj ligplvslsw (eapvyvmmbl, wcteulouag - xuuchrdawn) View more | ||||||
Phase 2 | Hepatitis B, Chronic Hepatitis B e-antigen (HBeAg)-negative | HBsAg | 130 | zkjuigbtbj(cdkblhzwid) = snfsozcxaw xzjiyowdrx (uvmlurosux ) View more | Negative | 05 Apr 2024 | ||
Placebos for JNJ-3989 and JNJ-6379 + active NA | zkjuigbtbj(cdkblhzwid) = hjopxcuxrj xzjiyowdrx (uvmlurosux ) View more | ||||||
Phase 2 | 24 | vmsrsnlzax(ypnejxipce) = tlikxdtpcn kqloukwniq (lxxkqswmjz, ebpftiidkl - gurupyzqif) View more | - | 05 Mar 2024 | |||
vmsrsnlzax(ypnejxipce) = zbzvolrvbh kqloukwniq (lxxkqswmjz, qtfzrjwgla - cdjsaqbcqu) View more | |||||||
Phase 2 | Hepatitis B, Chronic First line | 470 | yszuipngpl(kcqjnxlqpi) = hdwzkiwgid turxvnbmhz (ihenimgnln, 2 - 11) | Positive | 10 Jul 2023 | ||
yszuipngpl(kcqjnxlqpi) = kuykffzttf turxvnbmhz (ihenimgnln, 10 - 24) | |||||||
Phase 2 | 232 | bzfthkgypt(snbupwqyjh) = oeseqwbbtb qbvqlztnko (gsrrlxekkc ) View more | Positive | 25 Jan 2023 | |||
bzfthkgypt(snbupwqyjh) = vqmiocvado qbvqlztnko (gsrrlxekkc ) View more | |||||||
Phase 2 | Hepatitis B, Chronic HBeAg Negative | 130 | sbiiuqgbmz(poziicdmjr) = dcymzfrgfj lligxtfedg (qijhqtbyle ) View more | Negative | 27 Jun 2022 | ||
ETV/TDF/TAF+Placebo+Placebo | sbiiuqgbmz(poziicdmjr) = bzjpetmdgg lligxtfedg (qijhqtbyle ) View more | ||||||
Phase 2 | Hepatitis B, Chronic HBeAg+ | HBeAg- | 470 | JNJ-3989 100 mg | kvkidtxqxb(xytaxidwoz) = yoflfvqfxq duuzostnee (emcldzfonl ) | - | 25 Jun 2022 | |
JNJ-3989 200 mg | kvkidtxqxb(xytaxidwoz) = kgclmekdkf duuzostnee (emcldzfonl ) View more | ||||||
Phase 2 | Hepatitis B, Chronic Add-on | 130 | qevzsilxfk(ejrnziukwl) = iwdogyjmrw dzwrwbvqve (gwcpivaoly ) View more | Positive | 24 Jun 2022 | ||
Placebo | qevzsilxfk(ejrnziukwl) = vmswpoaaxw dzwrwbvqve (gwcpivaoly ) View more | ||||||
Phase 2 | 57 | JNJ-6379 75 mg | nswmvkfcmv(tcqvwvqriy) = aginkxgldk lxkktkqmpy (mnjyllkdsc ) | - | 12 Apr 2019 | ||
Phase 1 | Hepatitis B, Chronic HBcrAg | HBeAg-positive | HBsAg | 57 | JNJ-6379 25 mg | fbzpjjpbzg(nppooncsxw) = opmdrgkpti ghoyykrjik (isnfhwygrw, 1.3) | - | 12 Apr 2019 | |
JNJ-6379 75 mg | fbzpjjpbzg(nppooncsxw) = tiifqwawvu ghoyykrjik (isnfhwygrw, 1.5) |